XML 128 R63.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions (Details Textual) (USD $)
In Millions, unless otherwise specified
12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2012
Stromedix, Inc.
Mar. 08, 2012
Stromedix, Inc.
Mar. 07, 2012
Stromedix, Inc.
Dec. 31, 2012
Biogen Dompe SRL and Biogen Dompe Switzerland GmbH
Dec. 31, 2011
Biogen Dompe SRL and Biogen Dompe Switzerland GmbH
Sep. 06, 2011
Biogen Dompe SRL and Biogen Dompe Switzerland GmbH
Dec. 31, 2011
Biogen Dompe SRL
Sep. 06, 2011
Biogen Dompe SRL
Dec. 31, 2012
Biogen Idec International Neuroscience GmbH
Dec. 31, 2011
Biogen Idec International Neuroscience GmbH
Dec. 31, 2010
Biogen Idec International Neuroscience GmbH
Dec. 31, 2010
Biogen Idec Hemophilia
Dec. 31, 2012
Biogen Idec Hemophilia
Jan. 31, 2007
Biogen Idec Hemophilia
Mar. 08, 2012
STX One Hundred
Stromedix, Inc.
Business Acquisition                                    
Cash portion of consideration         $ 75.0       $ 152.9         $ 32.5        
Value of contingent consideration         487.5   38.5   42.5     387.5   395.0       275.0
Fair value of contingent consideration 293.9 151.0 81.2 135.3 122.2   29.8 31.9 38.8     128.8 119.1 81.2     80.0  
Discount rate used to calculate fair value of in process research and development                                   20.00%
In-process research and development         219.2                 110.9       202.6
Remaining cost to complete primary indication                                   290.0
Percentage of equity interest to the portion of total capital stock           5.00%                        
Recognized gain       9.0                            
Receivables purchased as part of acquisition                     104.6              
Loss recognized upon disposition                   1.8                
Stock acquired in acquisition                           100.00%     100.00%  
Goodwill         48.2                 25.6        
Milestone payments made during period             4.0         7.5     40.0      
Additional contingent payment for Biologic license                               20.0    
Additional contingent payment for marketing authorization                               $ 20.0